Astron Health is a precision oncology research company that develops bioinformatics platforms to support personalized cancer treatment. The company integrates genomic, transcriptomic, and proteomic data to improve treatment matching for cancer patients.
Operations
Astron Health was founded in 2024 to address limitations in conventional precision oncology, which primarily relies on genomic (DNA) testing to guide targeted cancer therapies.
Astron Health's scientific advisory board includes academic oncologists and clinicians such as Dr. Shivan Sivakumar, associate Professor of oncology at the University of Birmingham, and Dr. D. Barry Boyd, assistant professor of medicine (medical oncology) at Yale School of Medicine and Author of The Cancer Recovery Plan.
Astron Health's methodology is informed by published research highlighting limitations of genomic-only testing, including a 2020 study showing that some tumors harbor potentially deleterious DNA mutations that are not expressed at the RNA level, research demonstrating variable MAPK pathway activation in BRAF V600E–mutated melanoma despite identical genomic alterations and associated treatment resistance, and a 2022 study indicating that pathway-based molecular signatures may predict treatment response more accurately than mutation status alone.
Technology and approach
Astron Health provides a personalized oncology service that helps doctors choose the most effective cancer treatments by analyzing a patient's unique biological data. Their platform, known as the Polaris Research Report, combines three layers of molecular information—genetics, RNA expression, and protein activity—to see which parts of a tumor are actually functioning and vulnerable to specific drugs. By using artificial intelligence to scan thousands of medical studies and drug interactions, the company can also identify opportunities for drug repurposing, where existing medications or supplements might be effective against a specific pathway. Ultimately, these reports provide oncologists with a ranked list of evidence-based treatment options tailored to the specific molecular signature of a patient's cancer.